1
|
Huang Y, Chen H, Zhang L, Xie Y, Li C, Yu Z, Jiang Z, Zheng W, Li Z, Ge X, Liang Y, Wu Z. Design of Novel 18F-Labeled Amino Acid Tracers Using Sulfur 18F-Fluoride Exchange Click Chemistry. ACS Med Chem Lett 2024; 15:294-301. [PMID: 38352831 PMCID: PMC10860173 DOI: 10.1021/acsmedchemlett.3c00557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2023] [Revised: 01/16/2024] [Accepted: 01/22/2024] [Indexed: 02/16/2024] Open
Abstract
[18F]Gln-OSO2F, [18F]Arg-OSO2F, and [18F]FSY-OSO2F were designed by introducing sulfonyl 18F-fluoride onto glutamine, arginine, and tyrosine, respectively. [18F]FSY-OSO2F can be prepared directly by sulfur 18F-fluoride exchange, while [18F]Gln-OSO2F and [18F]Arg-OSO2F require a two-step labeling method. Those tracers retain their typical transport characteristics for unmodified amino acids. Both PET imaging and biodistribution confirmed that [18F]FSY-OSO2F visualized MCF-7 and 22Rv1 subcutaneous tumors with high contrast, and its tumor-to-muscle ratio was better than that of [18F]FET. However, [18F]Gln-OSO2F and [18F]Arg-OSO2F poorly image MCF-7 subcutaneous tumors, possibly due to differences in the types and amounts of transporters expressed in tumors. All three tracers can visualize the U87MG glioma. According to our biological evaluation, none of the tracers evaluated in this study exhibited obvious defluorination, and subtle structural changes led to different imaging characteristics, indicating that the application of sulfur 18F-fluoride exchange click chemistry in the design of radioactive sulfonyl fluoride amino acids is feasible and offers significant advantages.
Collapse
Affiliation(s)
- Yong Huang
- Department
of Nuclear Medicine, National Cancer Center, National Clinical Research
Center for Cancer, Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union
Medical College, Shenzhen 518116, China
| | - Hualong Chen
- Beijing
Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry
of Science and Technology, Collaborative Innovation Center for Brain
Disorders, Capital Medical University, Beijing 100069, China
| | - Lu Zhang
- Beijing
Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry
of Science and Technology, Collaborative Innovation Center for Brain
Disorders, Capital Medical University, Beijing 100069, China
| | - Yi Xie
- Beijing
Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry
of Science and Technology, Collaborative Innovation Center for Brain
Disorders, Capital Medical University, Beijing 100069, China
| | - Chengze Li
- Department
of Nuclear Medicine, National Cancer Center, National Clinical Research
Center for Cancer, Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union
Medical College, Shenzhen 518116, China
| | - Ziyue Yu
- Beijing
Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry
of Science and Technology, Collaborative Innovation Center for Brain
Disorders, Capital Medical University, Beijing 100069, China
| | - Zeng Jiang
- Beijing
Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry
of Science and Technology, Collaborative Innovation Center for Brain
Disorders, Capital Medical University, Beijing 100069, China
| | - Wei Zheng
- Beijing
Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry
of Science and Technology, Collaborative Innovation Center for Brain
Disorders, Capital Medical University, Beijing 100069, China
| | - Zhongjing Li
- Department
of Nuclear Medicine, National Cancer Center, National Clinical Research
Center for Cancer, Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union
Medical College, Shenzhen 518116, China
| | - Xuan Ge
- Beijing
Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry
of Science and Technology, Collaborative Innovation Center for Brain
Disorders, Capital Medical University, Beijing 100069, China
| | - Ying Liang
- Department
of Nuclear Medicine, National Cancer Center, National Clinical Research
Center for Cancer, Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union
Medical College, Shenzhen 518116, China
| | - Zehui Wu
- Beijing
Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry
of Science and Technology, Collaborative Innovation Center for Brain
Disorders, Capital Medical University, Beijing 100069, China
| |
Collapse
|